Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia

• Status: Withdrawn
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the clinical safety and tolerability of vabicaserin in Japanese subjects that have a sudden worsening of their symptoms of schizophrenia. The study will also assess the efficacy of vabicaserin and compare it to risperidone.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Risperidone

Criteria

Inclusion Criteria:

• Male and female subjects between >=20 and =<65 years of age

• Current diagnosis and DSM-IV-TR diagnosis of schizophrenia type (295.10, 295.30 and 295.90)

• Total PANSS score >=70 and =< 120

Exclusion Criteria:

• Subjects who are hospitalized against their will

• Current Axis I primary psychiatric diagnosis other than schizophrenia

• A score of 3 on CDSS question 8 which pertains to suicide